GRI Bio Inc. (GRI)
1.67
-0.35 (-17.33%)
At close: Apr 02, 2025, 3:59 PM
1.65
-1.24%
After-hours: Apr 02, 2025, 07:59 PM EDT
-17.33% (1D)
| Bid | 1.65 |
| Market Cap | 877.72K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -55.19 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | -0.68 |
| Analyst | Strong Buy |
| Ask | 1.65 |
| Volume | 2,439,911 |
| Avg. Volume (20D) | 218,570 |
| Open | 2.17 |
| Previous Close | 2.02 |
| Day's Range | 1.65 - 2.86 |
| 52-Week Range | 1.60 - 130.39 |
| Beta | -1.72 |
About GRI
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sc...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2021
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GRI
Website https://www.gribio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for GRI stock is "Strong Buy." The 12-month stock price forecast is $195.5, which is an increase of 11601.68% from the latest price.
Stock Forecasts1 day ago
-36.88%
GRI Bio shares are trading lower after the company...
Unlock content with
Pro Subscription
1 month ago
-4.45%
GRI Bio shares are trading lower after the company announced a 1-for-17 reverse stock split.
